BRACCO'S ACQUISITION OF SQUIBB DIAGNOSTICS
This article was originally published in The Gray Sheet
Executive SummaryBRACCO'S ACQUISITION OF SQUIBB DIAGNOSTICS creates a U.S. company with a broad diagnostic imaging agents pipeline, including contrast agents for x-ray, magnetic resonance imaging, and ultrasound, as well as radiopharmaceuticals. In addition to its core imaging products already on the market -- the x-ray imaging agent Isovue (iopamidol) and MRI contrast agent ProHance (gadoteridol) -- the Bristol-Myers Squibb subsidiary has at least three products in its pipeline.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.